No Data
No Data
Beijing Leadman Biochemistry (300289.SZ): The company's production of chemical raw materials does not include proteases.
Beijing Leadman Biochemistry (300289.SZ) stated on the investor interactive platform that the company currently does not have any reagent products available for detecting Klebsiella pneumoniae with high toxicity. The biochemical raw materials produced by the company do not contain proteases.
Beijing Leadman Biochemistry (300289.SZ): Currently not involved in anthrax testing reagent products.
On August 6, Gelunhui reported that Beijing Leadman Biochemistry (SZ.300289) stated on the investor interaction platform that the company is currently not involved in anthrax bacterial testing reagent products. At present, the company is using protease K as a raw material in the production of its testing reagent products.
Beijing Leadman Biochemistry (300289.SZ) is not subject to delisting risk warnings or other risk warnings.
Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform on July 23 that the company's current production and operation activities are all normal, and there is no situation of being subject to delisting risk warnings or other risk warnings. The stock price fluctuations in the secondary market are affected by various factors.
Beijing Leadman Biochemistry (300289.SZ) : JointMedicine repurchases 50% of the company's equity held in advance.
Leadman Biochemistry (300289.SZ) announced on July 9th that on November 8, 2022, the company signed the "Capital Increase Agreement of Shenzhen United Medical Technology Co., Ltd." and the "Shareholders Agreement of Shenzhen United Medical Technology Co., Ltd." with Shenzhen United Medical Technology Co., Ltd. (hereinafter referred to as "United Medical") and its shareholders. The company increased its capital by RMB 20 million of its own funds to United Medical and obtained 3.5088% equity. Recently, after negotiation between the company and United Medical, United Medical repurchased 50% of the company's equity held, while the company and United Medical reached an agreement with Guo Yong...
Beijing Leadman Biochemistry (300289.SZ): Currently there is no risk of special treatment (ST).
On July 4th, Gelonhui reported that Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform that the company currently does not have special treat risk. Regarding the accounting treatment of accounts receivable, the company will strictly follow the Enterprise Accounting Standards, relevant regulations, and regulatory requirements.
Beijing Leadman Biochemistry (300289.SZ) has not yet involved in CXO business.
Beijing Leadman Biochemistry (300289.SZ) stated on the investor interaction platform that the company is currently focusing on the in vitro diagnostics industry, and its business has not yet involved CXO. The company closely monitors market and industry development trends and actively seeks potential acquisition targets with business synergy.
No Data